Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study - Wikidata - wikimedia - TriplyDB

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

http://www.wikidata.org/entity/Q33827471

about

Parasitological, Hematological and Biochemical Characteristics of a Model of Hyper-microfilariaemic Loiasis (Loa loa) in the Baboon (Papio anubis)The chronic kalaemia conundrum Updates in hyperkalemia: Outcomes and therapeutic strategies.Renal tubular acidosis type IV in hyperkalaemic patients--a fairy tale or reality?Elevated baseline potassium level within reference range is associated with worse clinical outcomes in hospitalised patients Patient-reported and actionable safety events in CKD.Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study Evaluation of an Intravenous Potassium Dosing Algorithm for Hypokalemic Critically Ill Patients.Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease.Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.The relationship between serum potassium, potassium variability and in-hospital mortality in critically ill patients and a before-after analysis on the impact of computer-assisted potassium control.Lower serum potassium combined with lower sodium concentrations predict long-term mortality risk in hemodialysis patients Major barriers responsible for malnutrition in hemodialysis patients: challenges to optimal nutrition Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial Patient safety issues in CKD: core curriculum 2015.Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis.The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.Laboratory Profiles of Patients on Hemodialysis - A Retrospective One Year Study in a Rural Tertiary Care Hospital Plasma potassium, diuretic use and risk of developing chronic kidney disease in a predominantly White population.Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.Urinary Sodium and Potassium Excretion and CKD Progression.Critical Risk Results - An Update on International Initiatives.Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality Diuretic use in renal disease.Management of hyperkalaemia in chronic kidney disease.Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.Clinical perspectives on the rationale for potassium supplementation.How Dangerous Is Hyperkalemia?Potassium: friend or foe?Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis.Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study Does hypokalemia contribute to acute kidney injury in chronic laxative abuse?The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease.Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

P2860

Q28550781-8C37B627-B39F-4ADD-AF6D-98BF168B1627 Q28647234-04DC2C3C-6C83-4F5B-88F4-3FCEBC73379C Q30245585-0A8FEB72-0087-4AAC-A611-46FB742376B6 Q30420332-F0BC435E-B96B-4ADF-B629-DE373AFFFCAA Q33729193-39439B67-7871-4A36-BB2F-EF0853FED448 Q33814930-D0708CAA-7430-40FF-9F77-578696B0C116 Q33846660-8F50EBA8-8DAF-43C0-8994-20A61E0B9F6E Q34672569-69866C36-50CE-4D73-8F94-1599124DDAEA Q34812460-FEDADEBB-EBE6-4DE5-B2D1-8A0D429D0B90 Q34895375-940CAE1C-10DA-4FBE-B7C6-3C10212D8F84 Q35033355-4444A37D-38DF-4705-9225-F751F68D5F3E Q35059117-07553E18-224D-432F-8AC2-1889217B6A3D Q35089769-9249DD95-D42D-4A91-B1EC-81F599E15C97 Q35128415-3AF949A6-5698-47D7-9BA2-7E6E3826D9F5 Q35798287-41EAE65B-E8B0-47D9-A4C7-C6D2C83FF6CE Q35955524-59F51310-F467-4F71-8D05-356E31CEAF8B Q36017400-72E5482F-2D9A-4986-B138-978EBA4BC41E Q36221853-82D90866-295D-4D0B-84B0-276C8F0F0CF8 Q36323999-65546E17-E8DD-4F6E-BD40-91B737B876D2 Q36390782-BAFA6396-A9EA-4AA9-A7E9-57EBD45EEFCA Q36432845-BB8BB970-A1F5-4517-A044-353B167C63B5 Q36746060-175F922D-3871-4B63-A03C-9B2CF0E8F83C Q37155147-E045361B-D15A-45B9-9C9C-48AC1A717055 Q37520876-7E0DC653-0EF1-48A7-BEA3-D568F71706B1 Q37969997-6DEC4715-182E-47C0-8D66-2AF0117460A1 Q38249892-9CCDC323-4761-43E9-8D9A-8A70FBD1E43F Q38416821-14E11EC4-A657-450A-A957-3D937C9BE4E6 Q38470687-26347F8A-7EA2-4DFC-B4AD-E4B97F4F0132 Q38639874-897904EC-E87D-46B5-8A71-4E4F333891C6 Q38838019-529BED2C-A63C-40BA-A891-22277DFA1A02 Q39307527-8C3E2501-FE50-4280-9B16-F5AE74CA97C9 Q39577854-73F7ADC2-3E72-42FD-A8BB-032D593EC125 Q39720848-1E55928A-8ED2-4E70-A81E-31F6118028CC Q41154605-8C07A9D4-3D4B-4EA2-8330-82AE104838A1 Q41849559-9E2C1B42-5A90-43EC-A612-77D8791873BC Q44532842-29A47BF1-47AF-4F06-B3EE-DD1CA034CEC9 Q46622265-6C745457-1BF1-4057-9B1B-C3AC87AB5919 Q47126386-6EF1C84F-7C28-4B4C-9680-F6DEA4B9E83F Q47410763-35EA593F-BC6E-4585-B77A-CCB828393802 Q47669329-4BB10DF0-04CF-4580-A08F-79B103794D87

P2860

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

http://www.wikidata.org/entity/Q33827471

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@ast

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@en

type

label

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@ast

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@en

prefLabel

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@ast

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@en

P1433

Q33827471-09ACDCED-869E-44A9-B1B2-DE45D68B0D83

P1476

Q33827471-BD513763-171D-4173-AECB-191B2C27897C

P2093

Q33827471-0CABE2EB-3D1B-470A-8D6F-132AD7201795

Q33827471-44F95BC6-332A-49C2-A8E2-CD902B33AC9B

Q33827471-59A6300E-FC86-4D12-AB60-0E3DC27625C3

Q33827471-6B3A3AB4-A4C5-49C4-BF58-85CC1BDDA4D9

Q33827471-72E6B5DA-C77E-47CD-B132-3D757666F6D0

Q33827471-7B15B90F-B069-44DA-BEBF-14F9D3657B2E

Q33827471-9307A598-4071-4C60-B7E6-81D7E166482C

Q33827471-E956E282-D5F0-4F3E-A8B5-0C2086C56E60

P2860

Q33827471-0734D1FA-46E5-4BEB-A932-E9CF85C86B60

Q33827471-0F15F765-0A14-453B-BDDB-365AF7021701

Q33827471-12BC51EA-75EF-4125-BA32-6DCF43F0EE78

Q33827471-19A2C27F-5845-4105-B9AB-284A0D09B028

Q33827471-2DCF1E65-1A8B-4184-B722-C4FEA55F2D3D

Q33827471-418B3BFB-1693-45BA-AD00-91A1505ED78B

Q33827471-41A16296-324C-4931-AD08-AAD7715BC0DE

Q33827471-4774882E-989F-406C-A4CB-A093C9CC1E29

Q33827471-49704FB4-83CE-4915-B0FB-43E5DE552D01

Q33827471-5BA45DEF-1368-4344-9739-9DDD316DFDBE

P304

Q33827471-02482B31-5DCE-4B17-B4E5-AEF25DBB076F

P31

Q33827471-E9DA536C-866A-4C12-937A-CBA3864505A5

P356

Q33827471-2C6DB097-1459-4228-93FE-55186ACC0873

P433

Q33827471-D94B2075-3995-444F-809F-54E941F0F785

P478

Q33827471-613111A2-1167-4ABF-BCB2-79EAA8ECBDB5

P50

Q33827471-8BE576F1-D101-4083-BBA3-E163AE02C49D

P577

Q33827471-0DAA9BF6-7D05-48DF-A7D2-FD42A4834B33

P5875

Q33827471-A7A56303-3A7A-4AA2-AD96-0497BB27B8BE

P698

Q33827471-ED6DBB4D-22AF-40BE-8EAD-195F26A043FC

P932

Q33827471-7D53AE74-B0B3-4A74-8FF8-A4AA2A850C14

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

@en

P2093

Anca Tilea

http://www.w3.org/2001/XMLSchema#string

Brenda W Gillespie

http://www.w3.org/2001/XMLSchema#string

Fredric Finkelstein

http://www.w3.org/2001/XMLSchema#string

George Eisele

http://www.w3.org/2001/XMLSchema#string

Margaret Kiser

http://www.w3.org/2001/XMLSchema#string

Peter Kotanko

http://www.w3.org/2001/XMLSchema#string

Rajiv Saran

http://www.w3.org/2001/XMLSchema#string

Sonal Korgaonkar

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

ED hemodialysis for treatment of renal failure emergencies.

Hyperkalemia in hospitalized patients.

Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia

Mortality in heart failure: clinical variables of prognostic value

Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3.

Hyperkalemia: An adaptive response in chronic renal insufficiency.

Potassium metabolism in patients with chronic kidney disease (CKD), Part I: patients not on dialysis (stages 3-4).

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.

P304

762-769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05850809

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41760675

http://www.w3.org/2001/XMLSchema#string

P698

20203167

http://www.w3.org/2001/XMLSchema#string

P932

2863985

http://www.w3.org/2001/XMLSchema#string